(4aR,6R,7R,8R,8aS)-6-Methoxy-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxine-7,8-diamine | 38849-24-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (4aR,6R,7R,8R,8aS)-6-Methoxy-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxine-7,8-diamine
• 英文别名: (4aR,6R,7R,8R,8aS)-6-methoxy-2-phenyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxine-7,8-diamine
• CAS: 38849-24-0
• 化学式: C₁₄H₂₀N₂O₄
• 分子量: 280.324
• InChiKey: AIOJNMKYPYMIQY-ZZOOZXLSSA-N

物化性质

• 沸点：
  427.172±45.00 °C(Press: 760.00 Torr)(predicted)
• 密度：
  1.276±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  89
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  potassium tetrachloroplatinate(II) 、 (4aR,6R,7R,8R,8aS)-6-Methoxy-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxine-7,8-diamine 、 potassium iodide 以 水 、 甲醇 为溶剂， 反应 45.0h， 以95%的产率得到Pt((4aR,6R,7R,8R,8aS)-6-methoxy-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-7,8-diamine)I₂
  参考文献：
  名称：

  [EN] TRANSITION METAL-BASED FUNCTIONAL MOIETIES FOR PREPARING CELL TARGETING CONJUGATES
  [FR] FRAGMENTS FONCTIONNELS À BASE DE PLATINE POUR PRÉPARER DES CONJUGUÉS DE CIBLAGE CELLULAIRE

  摘要：

  公开号：

  WO2019125154A3

文献信息

• TRANSITION METAL-BASED FUNCTIONAL MOIETIES FOR PREPARING CELL TARGETING CONJUGATES
  申请人：LINXIS B.V.

  公开号：US20200345862A1

  公开（公告）日：2020-11-05

  The disclosure relates to secondary functional moieties comprising a transition metal-based linker and a primary functional moiety bound thereto. The disclosure also relates to cell targeting conjugates comprising a linker of the invention. The disclosure further relates to a medicament comprising the cell targeting conjugate and to the use of the cell targeting conjugates in the diagnosis and treatment of cancer.
• METHODS FOR PREPARING CELL TARGETING CONJUGATES AND CONJUGATES OBTAINABLE BY SAID METHODS
  申请人：LINXIS B.V.

  公开号：US20210113712A1

  公开（公告）日：2021-04-22

  Methods for preparing a cell targeting conjugate, which conjugate comprises a cell binding moiety conjugated to a secondary functional moiety. The disclosure further relates to the cell targeting conjugates obtainable by the method, to a pharmaceutical composition comprising the conjugates and to the secondary functional moieties as such. The disclosure also relates to the use of the cell targeting conjugates in the treatment of cancer.